NYSEAMERICAN:OCX - OncoCyte Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.60
  • Forecasted Upside: 76.47 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.74
▲ +0.04 (1.08%)

This chart shows the closing price for OCX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OncoCyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCX

Analyst Price Target is $6.60
▲ +76.47% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for OncoCyte in the last 3 months. The average price target is $6.60, with a high forecast of $11.00 and a low forecast of $4.00. The average price target represents a 76.47% upside from the last price of $3.74.

This chart shows the closing price for OCX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in OncoCyte. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/16/2021Needham & Company LLCReiterated RatingBuy$8.00
3/17/2021Needham & Company LLCReiterated RatingBuy$8.00
3/17/2021BenchmarkBoost Price TargetBuy$6.00 ➝ $11.00
1/7/2021BenchmarkUpgradeSpeculative Buy ➝ Buy$6.00
12/16/2020Piper SandlerUpgradeOverweight$2.00 ➝ $4.00
11/30/2020BTIG ResearchInitiated CoverageBuy$5.00
11/13/2020Piper SandlerBoost Price TargetNeutral$1.50 ➝ $2.00
11/13/2020Needham & Company LLCBoost Price TargetBuy$2.00 ➝ $4.00
11/10/2020KeyCorpInitiated CoverageOverweight$5.00
11/9/2020KeyCorpInitiated CoverageOverweight$5.00
10/21/2020Needham & Company LLCReiterated RatingBuy$2.00
10/2/2020Needham & Company LLCReiterated RatingBuy$2.00
7/30/2020BenchmarkLower Price TargetSpeculative Buy$7.00 ➝ $6.00
6/30/2020Chardan CapitalDowngradeBuy ➝ Neutral
6/30/2020Needham & Company LLCInitiated CoverageBuy$4.00
6/30/2020Piper SandlerDowngradeOverweight ➝ Neutral
6/30/2020Lake Street CapitalLower Price TargetBuy$6.00 ➝ $4.00
6/25/2020Piper SandlerBoost Price TargetOverweight$5.40 ➝ $7.50
6/17/2020Needham & Company LLCReiterated RatingBuy$4.00
6/2/2020Needham & Company LLCInitiated CoverageBuy$4.00
5/13/2020Chardan CapitalReiterated RatingBuy$7.75
3/26/2020Chardan CapitalReiterated RatingBuy$7.75
11/15/2019Chardan CapitalReiterated RatingBuy$7.75
7/3/2019BenchmarkReiterated RatingBuy
6/7/2019BenchmarkSet Price TargetBuy$7.00
5/17/2019Chardan CapitalSet Price TargetBuy$8.00
4/25/2019Chardan CapitalReiterated RatingBuy$7.75
4/2/2019Chardan CapitalReiterated RatingBuy$8.00
2/13/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$6.00 ➝ $6.00
1/29/2019Lake Street CapitalBoost Price TargetBuy$4.00 ➝ $7.00
1/29/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy
12/19/2018Lake Street CapitalReiterated RatingBuy ➝ Buy
9/10/2018Janney Montgomery ScottBoost Price Target$2.00 ➝ $4.00
7/11/2018BenchmarkInitiated CoverageBuy$7.00
3/21/2018Janney Montgomery ScottDowngradeBuy ➝ Neutral
5/23/2017Chardan CapitalBoost Price TargetBuy$6.50 ➝ $7.75
5/23/2017Chardan CapitalReiterated RatingBuy ➝ Buy$6.50 ➝ $7.75
2/23/2017Chardan CapitalInitiated CoverageBuy$6.50
1/30/2017Canaccord GenuityReiterated RatingBuy
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/29/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 5 negative mentions
  • 5 very negative mentions
8/28/2021
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
9/27/2021

Current Sentiment

  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

OncoCyte logo
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Read More

Today's Range

Now: $3.74
Low: $3.68
High: $3.74

50 Day Range

MA: $2.27
Low: $1.93
High: $2.63

52 Week Range

Now: $3.74
Low: $1.28
High: $6.57

Volume

1,860 shs

Average Volume

874,249 shs

Market Capitalization

$342.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of OncoCyte?

The following Wall Street analysts have issued stock ratings on OncoCyte in the last twelve months: Benchmark Co., BTIG Research, KeyCorp, Needham & Company LLC, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for OCX.

What is the current price target for OncoCyte?

5 Wall Street analysts have set twelve-month price targets for OncoCyte in the last year. Their average twelve-month price target is $6.60, suggesting a possible upside of 78.4%. Benchmark Co. has the highest price target set, predicting OCX will reach $11.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $4.00 for OncoCyte in the next year.
View the latest price targets for OCX.

What is the current consensus analyst rating for OncoCyte?

OncoCyte currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCX will outperform the market and that investors should add to their positions of OncoCyte.
View the latest ratings for OCX.

How do I contact OncoCyte's investor relations team?

OncoCyte's physical mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company's listed phone number is (949) 409-7600 and its investor relations email address is [email protected] The official website for OncoCyte is www.oncocyte.com.